ArticleScientific reports2025
Disproportionality analysis of infection associated with antidiabetic drug use patterns.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
While various antidiabetic drug classes are associated with differing infection risks, comprehensive evidence on infection risk across multidrug regimens remains limited. Therefore, this study aims to investigate the pharmacovigilance signal between antidiabetic drug use and infection risk, considering the number and patterns of drug use. This study evaluated the pharmacovigilance signal between antidiabetic drug use and infection utilizing the global pharmacovigilance database. To account for adverse events from multiple drug use, we restructured the database at the individual level using a unique demographic identifier, allowing assessment of infection risk by drug combination and count. Antidiabetic drugs include metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, and insulin, with infections categorized by the system. The pharmacovigilance signal of adverse drug reactions was estimated using adjusted reporting odds ratios (aRORs) with 95% confidence intervals (CIs) through multivariable logistic regression. SGLT2 inhibitor users reported the highest frequency of infections (n = 13,570), followed by insulin (n = 11,322) and GLP-1 RAs (n = 5966). When analyzing only monotherapy, excluding combination use, urinary tract infections were significantly linked solely to SGLT2 inhibitors (aROR, 10.41 [95% CI, 9.76-11.09]), while hepatobiliary and pancreatic infections were associated with DPP-4 inhibitors (aROR, 1.72 [95% CI, 1.28-2.31]), with no significant pharmacovigilance signal observed for other drug classes. Compared to monotherapy, combination therapy with two drugs (aROR, 1.24 [95% CI, 1.20-1.29]) or three or more drugs (aROR, 1.42 [95% CI, 1.13-1.79]) was associated with infection. Although the results from disproportionality analysis did not indicate causal relationship, our findings indicate that infection types vary between monotherapy and combination therapy, highlighting the need for further investigation into these pharmacovigilance signal due to the increased susceptibility of individuals with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.